Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

August 09, 2012 16:01 ET | Source: Alimera Sciences, Inc.

Alimera Sciences Reports Second Quarter 2012 Financial Results

Company Expects to Begin Generating Revenue in the First Quarter of 2013 Alimera Will Host a Conference Call at 4:30 P.M. ET Today ATLANTA, Aug. 9, 2012 (GLOBE NEWSWIRE) -- Alimera Sciences,...
July 30, 2012 12:15 ET | Source: Alimera Sciences, Inc.

Alimera Sciences to Release Second Quarter Fiscal Year 2012 Financial Results

ATLANTA, July 30, 2012 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq:ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of...
July 18, 2012 09:56 ET | Source: Alimera Sciences, Inc.

Alimera Sciences' ILUVIEN(R) Receives Marketing Authorization in France for the Treatment of Chronic Diabetic Macular Edema

ATLANTA, July 18, 2012 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc., (Nasdaq:ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of...
July 18, 2012 07:00 ET | Source: Alimera Sciences, Inc.

Alimera Sciences Agrees to Sell $40 Million of Convertible Preferred Stock

Company Hosting Analyst Day Today in NYC to Discuss Update on ILUVIEN Market Opportunity in Europe; Webcast Available for Replay Dr. Garheng Kong to join Board of Directors upon...
June 26, 2012 11:30 ET | Source: Alimera Sciences, Inc.

Alimera Sciences to Webcast 2012 Analyst Day

ATLANTA, June 26, 2012 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc., (Nasdaq:ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of...
June 05, 2012 08:00 ET | Source: Alimera Sciences, Inc.

Alimera Sciences' ILUVIEN(R) Receives Marketing Authorization in Portugal for the Treatment of Chronic Diabetic Macular Edema

ATLANTA, June 5, 2012 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc., (Nasdaq:ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of...
May 11, 2012 06:45 ET | Source: Alimera Sciences, Inc.

Alimera Sciences Reports First Quarter 2012 Financial Results

Cash and Cash Equivalents at March 31, 2012 Totaled $27.6 Million Alimera Will Host a Conference Call at 8:30 A.M. ET Today ATLANTA, May 11, 2012 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc.,...
May 07, 2012 08:30 ET | Source: Alimera Sciences, Inc.

United Kingdom Grants ILUVIEN(R) Marketing Authorization for the Treatment of Chronic Diabetic Macular Edema

ATLANTA, May 7, 2012 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc., (Nasdaq:ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of...
April 26, 2012 07:00 ET | Source: Alimera Sciences, Inc.

Alimera Sciences to Release First Quarter Fiscal Year 2012 Financial Results

ATLANTA, April 26, 2012 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc. (Nasdaq:ALIM) ("Alimera"), a biopharmaceutical company that specializes in the research, development and commercialization of...
April 24, 2012 08:30 ET | Source: Alimera Sciences, Inc.

ILUVIEN(R) Receives Marketing Authorization in Austria for the Treatment of Chronic Diabetic Macular Edema

ATLANTA, April 24, 2012 (GLOBE NEWSWIRE) -- Alimera Sciences, Inc., (Nasdaq:ALIM) (Alimera), a biopharmaceutical company that specializes in the research, development and commercialization of...